fda compounding semaglutide update Compounded GLP-1 Statistics 2026 |

Numerous evidences indicate that obesity leads to systemic chronic inflammation and is strongly associated with type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, along with many types of cancers (Rohm et al., 2022)

First: a once-weekly subcutaneous injection of semaglutide 1.0 mg (Ozempic), a glucagon-like peptide 1 analogue, was approved for the treatment of type 2 diabetes, and has proven to reduce the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease

GLP-1 medications should be used with a reduced-calorie meal plan and increased physical activity

It is modified for increased stability and longer duration of action

GLPs are synthetic analogues of naturally occurring GLP hormones that stimulate GLP-1 receptors